AIM: Receptor-specific small molecules and nanoparticles are widely used in molecular imaging of tumors. Although some studies have described the relative strengths and weaknesses of the two approaches, reports of a direct comparison and analysis of the two strategies are lacking. Herein, we compared the tumor-targeting characteristics of a small near-infrared fluorescent compound (cypate-peptide conjugate) and relatively large perfluorocarbon-based nanoparticles (250 nm diameter) for imaging alpha(nu)beta(3)-integrin receptor expression in tumors. MATERIALS & METHODS: Near-infrared fluorescent small molecules and nanoparticles were administered to living mice bearing subcutaneous or intradermal syngeneic tumors and imaged with whole-body and high-resolution optical imaging systems. RESULTS: The nanoparticles, designed for vascular constraint, remained within the tumor vasculature while the small integrin-avid ligands diffused into the tissue to target integrin expression on tumor and endothelial cells. Targeted small-molecule and nanoparticle contrast agents preferentially accumulated in tumor tissue with tumor-to-muscle ratios of 8 and 7, respectively, compared with 3 for nontargeted nanoparticles. CONCLUSION: Fluorescent small molecular probes demonstrate greater overall early tumor contrast and rapid visualization of tumors, but the vascular-constrained nanoparticles are more selective for detecting cancer-induced angiogenesis. A combination of both imaging agents provides a strategy to image and quantify integrin expression in tumor tissue and tumor-induced neovascular systems.
AIM: Receptor-specific small molecules and nanoparticles are widely used in molecular imaging of tumors. Although some studies have described the relative strengths and weaknesses of the two approaches, reports of a direct comparison and analysis of the two strategies are lacking. Herein, we compared the tumor-targeting characteristics of a small near-infrared fluorescent compound (cypate-peptide conjugate) and relatively large perfluorocarbon-based nanoparticles (250 nm diameter) for imaging alpha(nu)beta(3)-integrin receptor expression in tumors. MATERIALS & METHODS: Near-infrared fluorescent small molecules and nanoparticles were administered to living mice bearing subcutaneous or intradermal syngeneic tumors and imaged with whole-body and high-resolution optical imaging systems. RESULTS: The nanoparticles, designed for vascular constraint, remained within the tumor vasculature while the small integrin-avid ligands diffused into the tissue to target integrin expression on tumor and endothelial cells. Targeted small-molecule and nanoparticle contrast agents preferentially accumulated in tumor tissue with tumor-to-muscle ratios of 8 and 7, respectively, compared with 3 for nontargeted nanoparticles. CONCLUSION: Fluorescent small molecular probes demonstrate greater overall early tumor contrast and rapid visualization of tumors, but the vascular-constrained nanoparticles are more selective for detecting cancer-induced angiogenesis. A combination of both imaging agents provides a strategy to image and quantify integrin expression in tumor tissue and tumor-induced neovascular systems.
Authors: Kathryn C Crowder; Michael S Hughes; Jon N Marsh; Alejandro M Barbieri; Ralph W Fuhrhop; Gregory M Lanza; Samuel A Wickline Journal: Ultrasound Med Biol Date: 2005-12 Impact factor: 2.998
Authors: Anne H Schmieder; Patrick M Winter; Shelton D Caruthers; Thomas D Harris; Todd A Williams; John S Allen; Elizabeth K Lacy; Huiying Zhang; Michael J Scott; Grace Hu; J David Robertson; Samuel A Wickline; Gregory M Lanza Journal: Magn Reson Med Date: 2005-03 Impact factor: 4.668
Authors: Gregory M Lanza; Xin Yu; Patrick M Winter; Dana R Abendschein; Kerry K Karukstis; Michael J Scott; Lori K Chinen; Ralph W Fuhrhop; David E Scherrer; Samuel A Wickline Journal: Circulation Date: 2002-11-26 Impact factor: 29.690
Authors: David F Meoli; Mehran M Sadeghi; Svetlana Krassilnikova; Brian N Bourke; Frank J Giordano; Donald P Dione; Haili Su; D Scott Edwards; Shuang Liu; Thomas D Harris; Joseph A Madri; Barry L Zaret; Albert J Sinusas Journal: J Clin Invest Date: 2004-06 Impact factor: 14.808
Authors: Adah Almutairi; Walter J Akers; Mikhail Y Berezin; Samuel Achilefu; Jean M J Fréchet Journal: Mol Pharm Date: 2008 Nov-Dec Impact factor: 4.939
Authors: Mehran M Sadeghi; Svetlana Krassilnikova; Jiasheng Zhang; Amir A Gharaei; Hooman Rastegar Fassaei; Leila Esmailzadeh; Ali Kooshkabadi; Scott Edwards; Padmaja Yalamanchili; Thomas D Harris; Albert J Sinusas; Barry L Zaret; Jeffrey R Bender Journal: Circulation Date: 2004-06-21 Impact factor: 29.690
Authors: Y Chen; G Zheng; Z H Zhang; D Blessington; M Zhang; H Li; Q Liu; L Zhou; X Intes; S Achilefu; B Chance Journal: Opt Lett Date: 2003-11-01 Impact factor: 3.776
Authors: Patrick M Winter; Shelton D Caruthers; Andrea Kassner; Thomas D Harris; Lori K Chinen; John S Allen; Elizabeth K Lacy; Huiying Zhang; J David Robertson; Samuel A Wickline; Gregory M Lanza Journal: Cancer Res Date: 2003-09-15 Impact factor: 12.701
Authors: William C Zamboni; Vladimir Torchilin; Anil K Patri; Jeff Hrkach; Stephen Stern; Robert Lee; Andre Nel; Nicholas J Panaro; Piotr Grodzinski Journal: Clin Cancer Res Date: 2012-06-05 Impact factor: 12.531
Authors: Gregory M Lanza; Jon N Marsh; Grace Hu; Michael J Scott; Anne H Schmieder; Shelton D Caruthers; Dipanjan Pan; Samuel A Wickline Journal: Stroke Date: 2010-10 Impact factor: 7.914
Authors: Walter J Akers; Chulhong Kim; Mikhail Berezin; Kevin Guo; Ralph Fuhrhop; Gregory M Lanza; Georg M Fischer; Ewald Daltrozzo; Andreas Zumbusch; Xin Cai; Lihong V Wang; Samuel Achilefu Journal: ACS Nano Date: 2010-12-20 Impact factor: 15.881
Authors: Peter A Jarzyna; Lisette H Deddens; Benjamin H Kann; Sarayu Ramachandran; Claudia Calcagno; Wei Chen; Anita Gianella; Rick M Dijkhuizen; Arjan W Griffioen; Zahi A Fayad; Willem J M Mulder Journal: Neoplasia Date: 2012-10 Impact factor: 5.715
Authors: Tiffany P Gustafson; Ying Yan; Piyaraj Newton; Daniel A Hunter; Samuel Achilefu; Walter J Akers; Susan E Mackinnon; Philip J Johnson; Mikhail Y Berezin Journal: Medchemcomm Date: 2012-06-01 Impact factor: 3.597